Innovus Pharmaceuticals, Inc. ("Innovus Pharma") (OTCQB Venture Market: INNV), an emerging commercial-stage pharmaceutical company that delivers safe, innovative and effective over-the-counter medicine and consumer care products to improve men's and women's health and respiratory diseases, today announced the launch of Zestra® Multi-dose in the U.S. Approximately 43% of women age 18 to 59, or 50 million, experience some form of Female Sexual Dysfunction (FSD) according to a published study. (Laumann, E.O. et al. Sexual Dysfunction in the United States: Prevalence and Predictors. JAMA, Feb. 10, 1999. vol. 281, No. 6.537-542). The FSD market is estimated to be more than $1 billion per year. "Zestra® is the fourth Innovus product to be launched using our acquired Beyond Human sales and marketing platform and we currently believe the product could generate an additional $1.5 million a year in revenues, adding to the revenues already being generated by the retail and online sales of the product along with our revenues for Vesele®, Sensum+® and RecalMax™ dietary supplements," said Innovus CEO Dr. Bassam Damaj. "This launch is one more step towards achieving our 2017 corporate goals of $15 million in revenue and profitability." The product is available through www.zestra.com and through the Beyond Human print and online platform reaching between 20-30 million Americans on a monthly basis. About Zestra® and FSI/AD Zestra® is a patented blend of natural oils clinically-proven in double-blind placebo-controlled clinical trials in 276 women to increase in a statistical significant manner the arousal, desire and sexual satisfaction in FSI/AD women. Zestra® is the first NHP product to receive approval for the indication of FSI/AD in Canada. To date, no product has been approved to treat FSI/AD, a persistent or recurring inability to attain or maintain adequate sexual excitement until the completion of a sexual activity. The diagnosis can also refer to an inadequate lubrication-swelling response normally present during arousal and sexual activity causing personal distress. Published papers on the FSI/AD market size estimate it to be equal or larger than the market for erectile dysfunction in males, and possibly larger.